Drug Trial Radar · NCT00784147
Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1
Last checked: Nov 20, 2026Latest source record: May 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Aug 2008
Primary completion
Apr 2011
Study completion Apr 2011
Sponsor
- Lead sponsor
- TaiMed Biologics Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigational product, ibalizumab, is a humanized IgG4 monoclonal antibody administered via intravenous infusion at 800 mg every 2 weeks or at 2000 mg every 4 weeks. In addition to study drug, all patients will receive an optimized background regimen (OBR), which is a standard-of-care regimen selected by the investigator prior to randomization that is comprised of 2-4 antiretroviral agents. These agents must have been approved by the local regulatory agency or be available through expanded-access programs for treatment of human immunodeficiency virus (HIV).
Conditions
- HIV
Interventions
IbalizumabDrug
Ibalizumab 800 mg IV every 2 weeks
IbalizumabDrug
Ibalizumab 2000 mg IV every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Proportion of Patients Achieving Undetectable Viral Loads at Week 24.Time frame: 24 weeks
Locations
30 sites in 2 countries. Site status is shown where the registry gives one.
AIDS Health Care Foundation - Research
Beverly Hills, California
Living Hope Clinical Foundation
Long Beach, California
Kaiser Permanente Medical Center
Los Angeles, California
Quest Clinical Research
San Francisco, California
Kaiser Permanente Medical Center Research Unit
San Francisco, California
Kaiser Permanente of Colorado
Denver, Colorado
National Jewish Medical & Research Center
Denver, Colorado
Whitman-Walker Clinic
Washington D.C., District of Columbia
South Florida Clinical Research
Atlantis, Florida
University of Miami, Miller School of Medicine
Miami, Florida
Orlando Immunology Center
Orlando, Florida
Associates in Infectious Diseases
Port Saint Lucie, Florida
Treasure Coast Infectious Disease Consultants
Vero Beach, Florida
Triple O Medical Services, Inc.
West Palm Beach, Florida
Northstar Medical Center
Chicago, Illinois
Indiana University School of Medicine - Wishard Memorial Hospital
Indianapolis, Indiana
St. Michael's Medical Center
Newark, New Jersey
AIDS Community Research Initiative of America
New York, New York
The Brody School of Medicine at ECU
Greenville, North Carolina
The Research & Educational Group
Portland, Oregon
Central Texas Clinical Research
Austin, Texas
North Texas Infectious Disease Consultants
Dallas, Texas
Valley AIDS Council
Harlingen, Texas
Therapeutic Concepts
Houston, Texas
University of Texas Health Science Center
Houston, Texas
Nationsmed Clinical Research
Houston, Texas
Dr. Gordon E. Crofoot, MD, PA
Houston, Texas
Research Access Network
Houston, Texas
Clinical Research Puerto Rico
San Juan, Puerto Rico
HOPE Clinical Research
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.